Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease

The USFDA-approved immunosuppressive drug rapamycin (Rapa), despite its potency, is limited by poor bioavailability and a narrow therapeutic index. In this study, we sought to improve bioavailability of Rapa with subcutaneous (SC) administration and to test its therapeutic feasibility and practicali...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Pharm
Autors principals: Lee, Changrim, Guo, Hao, Klinngam, Wannita, Janga, Srikanth R., Yarber, Frances, Peddi, Santosh, Edman, Maria C., Tiwari, Nishant, Liu, Siyu, Louie, Stan G., Hamm-Alvarez, Sarah F., MacKay, J. Andrew
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6957305/
https://ncbi.nlm.nih.gov/pubmed/31095909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.9b00263
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars